They sue me because the medicine is illegal, but if it is legal, they say I can't afford it?

Chapter 346 $1000 billion.

……

"Sell it, but it certainly won't be for 1000 billion."

"Hmm...it could also be 1000 billion, but it's 1000 billion US dollars."

"As long as you give me $1000 billion now, I can sell this drug patent at any time. I can transfer it whenever I want."

Faced with this question, Chen Xuan responded frankly.

But the amount he said so calmly left everyone stunned.

The whole place fell silent in an instant, so quiet that you could hear a pin drop.

And in the next moment, everyone couldn't help but explode.

"Fuck, did I hear that right? $1000 billion?"

"Oh my god, Chen Xuan is kidding, right? I know 1000 billion is a bit low, but isn't $1000 billion too much?"

"Hiss, if he really sold the formula for the lung cancer drug, he would have become the richest man in China, and the richest man by a wide margin."

"That's different. The other richest people's figures are all based on stock market value, which is quite inflated, but his $1000 billion is real cash."

"Chen Xuan is awesome. His words always make me drop my jaw. I wouldn't even dream of $1000 billion."

"When he said $1000 billion, no one believed him. But now he's achieved it. Maybe $1000 billion is really possible."

"Some drugs can indeed generate sales of hundreds of billions of dollars, but I wonder if a lung cancer drug can possibly do that."

Everyone at the scene was discussing excitedly.

Everyone was extremely shocked by the 100 billion US dollars that Chen Xuan mentioned.

Although everyone believes that the value of the lung cancer drug is far more than 1000 billion yuan, they did not believe him before, but now they all know that they have been slapped in the face.

But even so, they still find it hard to believe that a specific drug for lung cancer can create a $1000 billion myth. No matter how great the market potential of this drug is, it is hard to believe that it will be worth $1000 billion.

Historically, there have indeed been drugs that have generated sales of over $1000 billion, but they still think it is incredible.

It is hard for them to believe that a new drug can achieve this level of success. It requires the right time, place and people, and the drug must have been on the market for many years without any competition to generate sales of hundreds of billions of dollars.

In the decades since the development of modern medicine, there are still few drugs that can do this.

For a drug with sales of hundreds of billions, it is not an exaggeration to say that it is one in a million.

In this case, the $1000 billion that Chen Xuan mentioned was difficult for them to accept.

Not only the onlookers, but even those pharmaceutical companies that still had a hopeful mentality, instantly lost this idea and did not even have the courage to bargain with him.

After all, the opening price is $1000 billion. Even if it can be bargained, how much can it be reduced?

You should know that there is no pharmaceutical company in China with a market value of more than 100 billion US dollars.

Chen Xuan’s drug patent exceeds the market value of these pharmaceutical companies, which is indeed hard to believe.

Even in the entire world, there are only a dozen or so pharmaceutical giants with a market value of more than $1000 billion.

Because of this, everyone thought that he had no intention of selling the patent for the lung cancer drug when he offered this price, but was just deliberately offering a sky-high price to scare away all pharmaceutical companies.

But that’s not what Chen Xuan meant.

Or maybe he did have this idea, but he didn't ask his sister-in-law for help.

He knew that $1000 billion was a price that no pharmaceutical company could accept, but he also believed that the lung cancer drug was worth $1000 billion.

"You think $1000 billion is an exaggeration, but I don't think so."

"Lijinto entered the market a decade after the first statin, when there were already three similar drugs with annual sales exceeding $10 billion."

"Even so, within three years of its launch, Lijinto surpassed similar drugs and became the first drug in the world to exceed $100 billion in annual sales, with cumulative sales exceeding $1500 billion."

Chen Xuan spoke slowly and gave an example.

This is a drug that has dominated for many years. Although it is not a drug of the same type, it is comparable.

The sales volume of 1500 billion US dollars has made it a legend among legends and it remains a myth to this day.

"And Humira, known as the "Ten-Year King of Medicines."

"Xiu Mei Yue has generated a total sales revenue of $2100 billion, and after 21 years, it still generated $241 billion to successfully defend the title."

"Even though Xiumeiyue is now nearing the end of its life cycle, its total sales are still expected to exceed $2500 billion."

"As for the new drug king, Keytruda, which was approved for marketing in 2014, its cumulative sales have already exceeded $100 billion for the first time. In 2013, it reached the top spot globally with sales of $28 billion."

When talking about the last medicine, Chen Xuan also emphasized his tone.

Although Keytruda's total sales are still far behind those of Lijinto and Xiumeiyue, it is still young and has just reached the top, and there is still endless potential.

As for the first two drugs, they have already passed their peak sales cycle and are now on a downward trend. Their annual sales will become less and less. Only Keytruda represents the future global drug king and has huge potential.

The reason why Chen Xuan mentioned it is because it is also an anti-cancer drug.

"Keytruda is also an anti-cancer drug. Its main indication is advanced melanoma, and it is also suitable for the treatment of some cancers."

"These indications make Keytruda a widely used anti-cancer drug. It can be used in conjunction with chemotherapy to achieve therapeutic effects, which is why it has such high sales."

"The lung cancer drug is also an anti-cancer drug. It is suitable for a wider range of patients and has indications for many other cancers besides lung cancer. It has a wider range of indications than Keytruda, and the market will only be larger than Keytruda."

Chen Xuan said directly, "Keytruda can break through $1000 billion in sales, and the lung cancer specific drug will break through $1000 billion even faster than Keytruda, and there will be no competitors for a long time."

As soon as these words came out, everyone was stunned.

Compared with Keytruda, the lung cancer specific drug does have greater advantages.

Although Keytruda is not used to treat lung cancer, they are both anti-cancer drugs and have many similarities.

In terms of treatment, specific drugs for lung cancer can directly treat lung cancer without the need for chemotherapy. They also have a restraining effect on some cancers and can prevent the disease from worsening.

In terms of the range of indications and effects, lung cancer specific drugs far exceed Keytruda, and not just by a little bit.

In this way, Keytruda can exceed 100 billion US dollars and become the world's leading drug.

The lung cancer drug will have the same potential and is indeed more likely to break through $1000 billion in sales faster.

"Hiss, now that Chen Xuan mentioned it, I don't think it's a problem."

"It is indeed very likely that the market value of lung cancer drugs will exceed $1000 billion, but it is only a possibility."

“Even if it can break through $1000 billion, pharmaceutical companies can’t just make a $1000 billion acquisition. They need a return.”

"If you spend $100 billion to acquire patents, then sales must reach at least $150 billion, or $200 billion to be suitable for investment."

"Yes, this will take at least ten years. If the returns are not big enough, it would be better to use the funds elsewhere."

"Chen Xuan didn't say he had to sell it. He just wanted $1000 billion to buy it from him. Essentially, he didn't want to sell it."

"The lung cancer drug created a sales myth of over 500 billion yuan upon its launch. I guess the giants are ready to make another move. If he doesn't ask for too much, how can he scare them away?"

After Chen Xuan's analysis,

Everyone thinks that $1000 billion in sales is not impossible.

Considering the market potential of lung cancer-specific drugs, this is highly likely to be achieved.

But even so, they don't think anyone would pay $1000 billion to acquire the formula.

Capital is meant to generate profits. If the returns are not big enough, they certainly would not spend $1000 billion to acquire a patent.

This kind of investment will take at least ten years to generate sufficient returns, so if the time cost is taken into account, it will cost at least $1500 billion.

Even for some capital pursuing high returns, at least they need to identify a specific drug for lung cancer that can generate $2000 billion in sales.

But the possibility is too low, and no capital dares to bet that these drugs for lung cancer can do the job.

Under such circumstances, a $1000 billion acquisition price is naturally impossible, which can only deter many pharmaceutical companies.

……